{{Rsnum
|rsid=1042597
|Gene=UGT1A8
|Chromosome=2
|position=233618225
|Orientation=plus
|GMAF=0.287
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
|Gene_s=UGT1A8
}}{{PharmGKB
|RSID=rs1042597
|Name_s=UGT1A8: c.518C>G, mRNA 581C>G, p.Ala173Gly, UGT1A8*2
|Gene_s=UGT1A8
|Feature=Exon/NonSyn
|Evidence=PubMed ID:19890249
|Annotation=Risk or phenotype-associated allele: UGT1A8 c.518G, p173Gly, UGT1A8*2. Phenotype: The UGT1A8 C518G SNP tended to be associated with mycophenolic acid (MPA) C(0) (p = 0.0130), Cmax (p = 0.0368), and AUC(0-12 hours) (p = 0.0171), but not with exposure to its glucuronide, MPAG. Study size: 115. Study population/ethnicity: Caucasian cohort from the SOPHIE study who received cyclosporine in addition to Mycophenylate mofetil (MMF). Significance metric(s): p < 0.04. Type of association: GN; PK
|Drugs=cyclosporine; mycophenolate mofetil; mycophenolic acid
|Drug Classes=
|Diseases=Organ Transplantation
|Curation Level=Curated
|PharmGKB Accession ID=PA165109805
}}

{{PharmGKB
|RSID=rs1042597
|Name_s=UGT1A8: UGT1A8*1, reference allele, defined as: 173Ala, 255Thr, 277Cys; other definition see PMID: 9535849)
|Gene_s=UGT1A8
|Feature=Exon/NonSyn
|Evidence=PubMed ID:12042666
|Annotation=Risk or phenotype-associated allele: UGT1A8*1 (reference allele defined as: 173Ala, 255Thr, 277Cys; other definition see PMID: 9535849). Phenotype: In vitro catalytic activity and protein expression. Genetic analysis of UGT1A8 (exclusively expressed in extrahepatic tissue) in 69 individuals identified four alleles, of which the reference allele, UGT1A8*1, showed the greatest prevalence (0.55 allele frequency, 39% *1/*1 diplotype, in 71% of all diplotypes) in the population studied, and was defined as having 173Ala, 255Thr, 277Cys. In vitro studies in HEK293 cells show UGT1A8*1 has little impact on function and protein expression. Study size: 69. Study population/ethnicity: Lung cancer patients and family members and other volunteers who served as controls. Type of association: GN; FA
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165109779
}}

{{PharmGKB
|RSID=rs1042597
|Name_s=UGT1A8: UGT1A8*2, defined by rs1042597 c.518C>G, mRNA 581C>G, p.Ala173Gly
|Gene_s=UGT1A8
|Feature=Exon/NonSyn
|Evidence=PubMed ID:12042666
|Annotation=Risk or phenotype-associated allele: UGT1A8*2 (defining allele: 518C>G, Ala173Gly; other definitions see PMIDs: 9647757, 9705221). Phenotype: In vitro catalytic activity and protein expression. Genetic analysis of UGT1A8 (exclusively expressed in extrahepatic tissue) in 69 individuals identified four alleles, of which UGT1A8*2 was defined as having glycine at amino acid 173. In vitro studies in HEK293 cells show UGT1A8*2 has little impact on function. Study size: 69. Study population/ethnicity: Lung cancer patients and family members and other volunteers who served as controls. Type of association: GN; FA
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165109783
}}